Stonepine Capital Management LLC Purchases New Stake in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP)

Stonepine Capital Management LLC purchased a new stake in shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) during the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 535,805 shares of the company’s stock, valued at approximately $809,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. JPMorgan Chase & Co. raised its position in shares of PMV Pharmaceuticals by 2,282.8% during the 4th quarter. JPMorgan Chase & Co. now owns 24,591 shares of the company’s stock valued at $37,000 after acquiring an additional 23,559 shares in the last quarter. Northern Trust Corp increased its position in PMV Pharmaceuticals by 23.2% in the fourth quarter. Northern Trust Corp now owns 107,340 shares of the company’s stock worth $162,000 after buying an additional 20,190 shares during the period. Bridgeway Capital Management LLC increased its position in PMV Pharmaceuticals by 44.5% in the fourth quarter. Bridgeway Capital Management LLC now owns 202,100 shares of the company’s stock worth $305,000 after buying an additional 62,200 shares during the period. Peapod Lane Capital LLC acquired a new stake in PMV Pharmaceuticals in the fourth quarter worth $673,000. Finally, Aldebaran Capital LLC increased its position in PMV Pharmaceuticals by 14.6% in the fourth quarter. Aldebaran Capital LLC now owns 502,190 shares of the company’s stock worth $758,000 after buying an additional 63,938 shares during the period. 90.20% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $5.00 target price on shares of PMV Pharmaceuticals in a research report on Thursday, March 20th.

PMV Pharmaceuticals Price Performance

Shares of NASDAQ PMVP opened at $0.87 on Friday. PMV Pharmaceuticals, Inc. has a 1-year low of $0.81 and a 1-year high of $2.22. The business’s fifty day moving average price is $1.03 and its two-hundred day moving average price is $1.33. The firm has a market capitalization of $44.99 million, a PE ratio of -0.87 and a beta of 1.50.

PMV Pharmaceuticals (NASDAQ:PMVP) last issued its earnings results on Friday, May 9th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.03. Equities research analysts expect that PMV Pharmaceuticals, Inc. will post -1.06 earnings per share for the current fiscal year.

PMV Pharmaceuticals Company Profile

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.